Symbols / VKTX
VKTX Chart
About
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.90B |
| Enterprise Value | 3.19B | Income | -359.64M | Sales | — |
| Book/sh | 5.57 | Cash/sh | 6.11 | Dividend Yield | — |
| Payout | 0.00% | Employees | 53 | IPO | — |
| P/E | — | Forward P/E | -7.38 | PEG | — |
| P/S | — | P/B | 6.06 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 9.21 |
| Current Ratio | 9.33 | Debt/Eq | 0.02 | LT Debt/Eq | — |
| EPS (ttm) | -3.19 | EPS next Y | -4.57 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-04-29 | ROA | -30.28% |
| ROE | -47.34% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 115.55M |
| Shs Float | 112.73M | Short Float | 27.63% | Short Ratio | 7.79 |
| Short Interest | — | 52W High | 43.15 | 52W Low | 18.92 |
| Beta | 0.77 | Avg Volume | 2.97M | Volume | 2.25M |
| Target Price | $92.72 | Recom | Strong_buy | Prev Close | $34.46 |
| Price | $33.75 | Change | -2.06% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$92.72
Mean price target
2. Current target
$33.75
Latest analyst target
3. DCF / Fair value
$-24.96
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$33.75
Low
$35.00
High
$125.00
Mean
$92.72
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-12 | main | Canaccord Genuity | Buy → Buy | $107 |
| 2025-10-29 | init | Canaccord Genuity | — → Buy | $106 |
| 2025-10-24 | main | JP Morgan | Overweight → Overweight | $75 |
| 2025-10-23 | main | Morgan Stanley | Overweight → Overweight | $102 |
| 2025-09-29 | reit | HC Wainwright & Co. | Buy → Buy | $102 |
| 2025-09-22 | reit | BTIG | Buy → Buy | $125 |
| 2025-08-19 | reit | HC Wainwright & Co. | Buy → Buy | $102 |
| 2025-07-24 | main | Raymond James | Strong Buy → Strong Buy | $122 |
| 2025-07-24 | main | Citigroup | Neutral → Neutral | $38 |
| 2025-06-25 | reit | HC Wainwright & Co. | Buy → Buy | $102 |
| 2025-04-28 | init | Cantor Fitzgerald | — → Overweight | $104 |
| 2025-04-28 | reit | Truist Securities | Buy → Buy | $75 |
| 2025-04-24 | main | Morgan Stanley | Overweight → Overweight | $102 |
| 2025-04-24 | reit | HC Wainwright & Co. | Buy → Buy | $102 |
| 2025-04-17 | reit | HC Wainwright & Co. | Buy → Buy | $102 |
| 2025-04-08 | init | Goldman Sachs | — → Neutral | $30 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $102 |
| 2025-03-11 | reit | HC Wainwright & Co. | Buy → Buy | $102 |
| 2025-02-13 | init | Scotiabank | — → Sector Outperform | $102 |
| 2025-02-07 | init | Citigroup | — → Neutral | $38 |
- Why Viking Therapeutics Stock Is Up More Than 9% Today - Yahoo Finance Mon, 23 Feb 2026 18
- Viking Therapeutics Stock Jumps 11% After Obesity Drug Update: Analysts See $93 Target - TIKR.com ue, 24 Feb 2026 20
- Is Viking Therapeutics Stock Really Going to $125? - The Motley Fool hu, 19 Feb 2026 20
- Viking Therapeutics Advances VK2735 As Phase 3 Trials Shape Valuation - simplywall.st Wed, 25 Feb 2026 11
- $VKTX stock is up 12% today. Here's what we see in our data. - Quiver Quantitative Mon, 23 Feb 2026 14
- VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report - Stocktwits ue, 03 Feb 2026 08
- Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - PR Newswire Wed, 11 Feb 2026 08
- Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Bitget ue, 24 Feb 2026 16
- Viking Therapeutics, Inc. (VKTX) Stock Analysis: Evaluating a 219.73% Potential Upside in Biotech Innovation - DirectorsTalk Interviews ue, 17 Feb 2026 18
- Viking Therapeutics: Full-Speed Ahead (NASDAQ:VKTX) - Seeking Alpha Sat, 14 Feb 2026 08
- Viking Therapeutics Stock Gains Amid Obesity Drug Buzz - Benzinga Mon, 23 Feb 2026 19
- Viking Therapeutics Stock (VKTX) Opinions on Novo Nordisk CagriSema Setback - Quiver Quantitative Mon, 23 Feb 2026 17
- 3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds - The Motley Fool Mon, 23 Feb 2026 10
- Is Viking Therapeutics (VKTX) Offering Value After Recent Share Price Weakness - Yahoo Finance Wed, 04 Feb 2026 08
- Viking Therapeutics (VKTX) Valuation In Focus As VK2735 Advances In GLP 1 Weight Loss Trials - simplywall.st Mon, 23 Feb 2026 19
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 57661 | 1896969 | — | Sale at price 32.09 - 34.24 per share. | ZANTE GREGORY S | Chief Financial Officer | — | 2026-01-05 00:00:00 | D |
| 1 | 233409 | 7692121 | — | Sale at price 32.29 - 35.07 per share. | LIAN BRIAN | Chief Executive Officer | — | 2026-01-05 00:00:00 | D |
| 2 | 57661 | 1901405 | — | Sale at price 32.29 - 35.07 per share. | MANCINI MARIANNA | Chief Operating Officer | — | 2026-01-05 00:00:00 | D |
| 3 | 3150 | — | — | Stock Award(Grant) at price 0.00 per share. | FOEHR MATTHEW W | Director | — | 2026-01-02 00:00:00 | D |
| 4 | 16000 | 561694 | — | Sale at price 35.11 per share. | FOEHR MATTHEW W | Director | — | 2026-01-02 00:00:00 | D |
| 5 | 16000 | 53280 | — | Conversion of Exercise of derivative security at price 3.33 per share. | FOEHR MATTHEW W | Director | — | 2026-01-02 00:00:00 | D |
| 6 | 3150 | — | — | Stock Award(Grant) at price 0.00 per share. | SINGLETON J MATTHEW | Director | — | 2026-01-02 00:00:00 | D |
| 7 | 73049 | — | — | Stock Award(Grant) at price 0.00 per share. | ZANTE GREGORY S | Chief Financial Officer | — | 2026-01-02 00:00:00 | D |
| 8 | 3150 | — | — | Stock Award(Grant) at price 0.00 per share. | ROWLAND CHARLES A JR | Director | — | 2026-01-02 00:00:00 | D |
| 9 | 3150 | — | — | Stock Award(Grant) at price 0.00 per share. | MACARTNEY LAWSON | Director | — | 2026-01-02 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -392.97M | -150.69M | -100.53M | -70.02M |
| TotalUnusualItems | 55.00K | 112.00K | -42.00K | 7.00K |
| TotalUnusualItemsExcludingGoodwill | 55.00K | 112.00K | -42.00K | 7.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -359.64M | -109.96M | -85.89M | -68.87M |
| ReconciledDepreciation | 431.00K | 346.00K | 292.00K | 291.00K |
| EBITDA | -392.91M | -150.57M | -100.53M | -70.06M |
| EBIT | -393.34M | -150.92M | -100.83M | -70.36M |
| NetInterestIncome | 33.65M | 40.85M | 14.93M | 1.53M |
| InterestIncome | 33.70M | 40.94M | 15.02M | 1.59M |
| NormalizedIncome | -359.69M | -110.08M | -85.89M | -68.83M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -359.64M | -109.96M | -85.89M | -68.87M |
| TotalExpenses | 393.34M | 150.92M | 100.83M | 70.36M |
| TotalOperatingIncomeAsReported | -393.34M | -150.92M | -100.83M | -70.36M |
| DilutedAverageShares | 109.04M | 94.35M | 76.83M | 77.20M |
| BasicAverageShares | 109.04M | 94.35M | 76.83M | 77.20M |
| DilutedEPS | -1.01 | -0.91 | -0.90 | -0.71 |
| BasicEPS | -1.01 | -0.91 | -0.90 | -0.71 |
| DilutedNIAvailtoComStockholders | -359.64M | -109.96M | -85.89M | -68.87M |
| NetIncomeCommonStockholders | -359.64M | -109.96M | -85.89M | -68.87M |
| NetIncome | -359.64M | -109.96M | -85.89M | -68.87M |
| NetIncomeIncludingNoncontrollingInterests | -359.64M | -109.96M | -85.89M | -68.87M |
| NetIncomeContinuousOperations | -359.64M | -109.96M | -85.89M | -68.87M |
| PretaxIncome | -359.64M | -109.96M | -85.89M | -68.87M |
| OtherIncomeExpense | 55.00K | 112.00K | -42.00K | 7.00K |
| GainOnSaleOfSecurity | 55.00K | 112.00K | -42.00K | 7.00K |
| NetNonOperatingInterestIncomeExpense | 33.65M | 40.85M | 14.93M | 1.53M |
| TotalOtherFinanceCost | 56.00K | 94.00K | 88.00K | 59.00K |
| InterestIncomeNonOperating | 33.70M | 40.94M | 15.02M | 1.59M |
| OperatingIncome | -393.34M | -150.92M | -100.83M | -70.36M |
| OperatingExpense | 393.34M | 150.92M | 100.83M | 70.36M |
| ResearchAndDevelopment | 344.95M | 101.64M | 63.81M | 54.23M |
| SellingGeneralAndAdministration | 48.39M | 49.28M | 37.02M | 16.12M |
| GeneralAndAdministrativeExpense | 48.39M | 49.28M | 37.02M | 16.12M |
| OtherGandA | 48.39M | 49.28M | 37.02M | 16.12M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | 2022-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 2.19M | 2.19M | ||
| OrdinarySharesNumber | 114.79M | 111.57M | 100.11M | 78.26M |
| ShareIssued | 114.79M | 111.57M | 102.31M | 80.45M |
| TotalDebt | 137.00K | 1.12M | 1.26M | 1.56M |
| TangibleBookValue | 639.06M | 880.28M | 348.42M | 145.32M |
| InvestedCapital | 639.06M | 880.28M | 348.42M | 145.32M |
| WorkingCapital | 638.93M | 879.80M | 348.09M | 145.09M |
| NetTangibleAssets | 639.06M | 880.28M | 348.42M | 145.32M |
| CapitalLeaseObligations | 137.00K | 1.12M | 1.26M | 1.56M |
| CommonStockEquity | 639.06M | 880.28M | 348.42M | 145.32M |
| TotalCapitalization | 639.06M | 880.28M | 348.42M | 145.32M |
| TotalEquityGrossMinorityInterest | 639.06M | 880.28M | 348.42M | 145.32M |
| StockholdersEquity | 639.06M | 880.28M | 348.42M | 145.32M |
| GainsLossesNotAffectingRetainedEarnings | 378.00K | -788.00K | -389.00K | -1.10M |
| OtherEquityAdjustments | 378.00K | -788.00K | -389.00K | -1.10M |
| TreasuryStock | 0.00 | 0.00 | 6.79M | 6.79M |
| RetainedEarnings | -847.55M | -487.91M | -377.94M | -292.05M |
| AdditionalPaidInCapital | 1.49B | 1.37B | 733.55M | 445.27M |
| CapitalStock | 1.00K | 1.00K | 1.00K | 1.00K |
| CommonStock | 1.00K | 1.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 76.67M | 28.04M | 20.07M | 23.21M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 630.00K | 936.00K | 1.26M |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 630.00K | 936.00K | 1.26M |
| LongTermCapitalLeaseObligation | 0.00 | 630.00K | 936.00K | 1.26M |
| CurrentLiabilities | 76.67M | 27.41M | 19.14M | 21.95M |
| CurrentDebtAndCapitalLeaseObligation | 137.00K | 489.00K | 324.00K | 304.00K |
| CurrentCapitalLeaseObligation | 137.00K | 489.00K | 324.00K | 304.00K |
| PayablesAndAccruedExpenses | 76.53M | 26.92M | 18.81M | 21.64M |
| CurrentAccruedExpenses | 23.28M | 17.11M | 11.30M | 13.11M |
| Payables | 53.25M | 9.81M | 7.51M | 8.53M |
| AccountsPayable | 53.25M | 9.81M | 7.51M | 8.53M |
| TotalAssets | 715.73M | 908.32M | 368.49M | 168.53M |
| TotalNonCurrentAssets | 131.00K | 1.10M | 1.26M | 1.49M |
| NonCurrentPrepaidAssets | 46.00K | 46.00K | 33.00K | 33.00K |
| NonCurrentDeferredAssets | 0.00 | 56.00K | 106.00K | 38.00K |
| NetPPE | 85.00K | 1.00M | 1.13M | 1.42M |
| GrossPPE | 85.00K | 1.00M | 1.13M | 1.42M |
| BuildingsAndImprovements | 85.00K | 1.00M | 1.13M | 1.42M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 715.60M | 907.22M | 367.23M | 167.04M |
| OtherCurrentAssets | 1.81M | 1.13M | 2.52M | 3.41M |
| PrepaidAssets | 8.05M | 3.48M | 2.62M | 8.14M |
| CashCashEquivalentsAndShortTermInvestments | 705.74M | 902.61M | 362.08M | 155.49M |
| OtherShortTermInvestments | 539.93M | 875.94M | 306.56M | 118.85M |
| CashAndCashEquivalents | 165.81M | 26.68M | 55.52M | 36.63M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -278.69M | -87.79M | -73.38M | -48.40M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 | -6.82M | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 597.09M | 269.76M | |
| EndCashPosition | 165.81M | 26.68M | 55.52M | 36.63M |
| BeginningCashPosition | 26.68M | 55.52M | 36.63M | 26.37M |
| EffectOfExchangeRateChanges | -8.00K | -148.00K | -30.00K | -258.00K |
| ChangesInCash | 139.14M | -28.69M | 18.91M | 10.52M |
| FinancingCashFlow | 76.44M | 612.46M | 271.38M | 4.16M |
| CashFlowFromContinuingFinancingActivities | 76.44M | 612.46M | 271.38M | 4.16M |
| NetOtherFinancingCharges | 73.95M | 4.56M | -5.15M | 10.13M |
| ProceedsFromStockOptionExercised | 2.49M | 10.81M | 6.77M | 848.00K |
| NetCommonStockIssuance | 0.00 | 597.09M | 269.76M | -6.82M |
| CommonStockPayments | 0.00 | 0.00 | -6.82M | 0.00 |
| CommonStockIssuance | 0.00 | 597.09M | 269.76M | |
| InvestingCashFlow | 341.39M | -553.37M | -179.09M | 54.75M |
| CashFlowFromContinuingInvestingActivities | 341.39M | -553.37M | -179.09M | 54.75M |
| NetInvestmentPurchaseAndSale | 341.39M | -553.37M | -179.09M | 54.75M |
| SaleOfInvestment | 759.42M | 560.00M | 299.22M | 176.18M |
| PurchaseOfInvestment | -418.04M | -1.11B | -478.30M | -121.43M |
| OperatingCashFlow | -278.69M | -87.79M | -73.38M | -48.40M |
| CashFlowFromContinuingOperatingActivities | -278.69M | -87.79M | -73.38M | -48.40M |
| ChangeInWorkingCapital | 48.98M | 9.36M | 3.55M | 10.19M |
| ChangeInOtherCurrentLiabilities | -505.00K | -402.00K | -347.00K | -189.00K |
| ChangeInPayablesAndAccruedExpense | 49.61M | 8.12M | -2.83M | 12.89M |
| ChangeInAccruedExpense | 6.17M | 5.82M | -1.82M | 5.81M |
| ChangeInInterestPayable | 614.00K | 1.18M | ||
| ChangeInPayable | 43.44M | 2.30M | -1.02M | 7.08M |
| ChangeInAccountPayable | 43.44M | 2.30M | -1.02M | 7.08M |
| ChangeInPrepaidAssets | -5.20M | 446.00K | 6.41M | -3.13M |
| ChangeInReceivables | 5.08M | 1.20M | 321.00K | 614.00K |
| OtherNonCashItems | 66.00K | 132.00K | 131.00K | 100.00K |
| StockBasedCompensation | 40.82M | 29.71M | 16.75M | 8.67M |
| AmortizationOfSecurities | -9.28M | -17.27M | -8.20M | 1.22M |
| DepreciationAmortizationDepletion | 431.00K | 346.00K | 292.00K | 291.00K |
| DepreciationAndAmortization | 431.00K | 346.00K | 292.00K | 291.00K |
| Depreciation | 431.00K | 346.00K | 292.00K | 291.00K |
| OperatingGainsLosses | -55.00K | -112.00K | ||
| GainLossOnInvestmentSecurities | -55.00K | -112.00K | ||
| NetIncomeFromContinuingOperations | -359.64M | -109.96M | -85.89M | -68.87M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for VKTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|